Houlihan Lokey Advises KabaFusion (1)

Houlihan Lokey is pleased to announce that KabaFusion, a portfolio company of Brown Brothers Harriman Capital Partners (BBHCP), has been recapitalized by Pritzker Private Capital. 

Headquartered in Cerritos, California, KabaFusion was founded in 2010 by Sohail Masood, Pharm D., a pioneer in immunoglobulin infusion with over 25 years of experience in home infusion services. With its seven fully accredited specialty pharmacies, the company serves patients with a broad range of acute and chronic conditions in more than 40 states, specializing in intravenous immunoglobulin (IVIG) and other home infusion therapies.

BBHCP, a private equity strategy of Brown Brothers Harriman & Co., provides friendly capital solutions to growth-oriented middle-market companies. The firm’s flexible investment mandate gives them the ability to act as a control or non-control investor. BBHCP typically invests $30–$125 million per platform investment, and the firm’s capital is used to support a variety of transactions, including management or leveraged buyouts, growth financings, recapitalizations (including dividend recapitalizations), buy-and-build strategies and acquisitions.

Pritzker Private Capital acquires and operates middle-market companies based in North America with leading positions in the manufactured products, services and healthcare sectors. The firm’s differentiated, long-duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur and family-owned companies.

This transaction further strengthens Houlihan Lokey's leadership position in the pharmacy sector, becoming its fifth closed M&A transaction in this space over the past three years. Houlihan Lokey's Healthcare Group is among the largest dedicated healthcare investment banking groups in the country. In 2018, the group was ranked the No. 1 M&A advisor for all U.S. healthcare transactions by Thomson Reuters.